ENTA

+ Watchlist + Portfolio

Enanta Pharmaceuticals, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $13.51
52-Week Range: $7.05 – $17.15
Market Cap: $382.42M
P/E (TTM): —
EPS (TTM): -2.42
Dividend Yield: —

Advanced Metrics

Price/Book: 3.78
PEG Ratio: —
Return on Equity: -70.12%
Return on Assets: -12.28%
Gross Margin: 100.00%
Operating Margin: -120.04%
Profit Margin: -96.89%
Current Ratio: 3.76
Debt/Equity: 1.80
Total Debt: $182.04M
Free Cash Flow: $-22.66M
Revenue Growth: -21.60%
Earnings Growth: —
Enterprise Value: $386.02M

ENTA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$86.16M	$79.20M	$67.64M	$65.32M
Research & Development	$164.52M	$163.52M	$131.48M	$106.74M
Selling, General & Admin	$45.48M	$52.89M	$57.85M	$43.93M
Operating Expenses	$210.00M	$216.41M	$189.33M	$150.67M
Operating Income	-$123.84M	-$137.21M	-$121.69M	-$85.35M
EBITDA	-$119.22M	-$123.48M	-$104.51M	-$71.28M
Pretax Income	-$122.19M	-$131.00M	-$117.79M	-$83.55M
Income Tax	-$433.00K	$2.82M	-$1.74M	-$1.66M
Net Income	-$121.75M	-$133.82M	-$116.05M	-$81.89M
Diluted EPS	-5.91	-6.38	-5.48	-3.84
Diluted Shares	20.60M	20.97M	21.16M	21.34M

ENTA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$43.99M	$85.39M	$37.23M	$32.30M
Receivables	$49.04M	$39.62M	$38.65M	$6.88M
Current Assets	$311.71M	$422.79M	$299.85M	$204.34M
Total Assets	$375.41M	$462.27M	$376.65M	$280.73M
Current Liabilities	$29.83M	$62.79M	$57.53M	$48.55M
Total Debt	$25.26M	$26.51M	$55.47M	$57.90M
Total Liabilities	$54.08M	$245.54M	$247.84M	$216.01M
Retained Earnings	-$73.18M	-$207.00M	-$323.04M	-$404.93M
Shareholders' Equity	$321.33M	$216.74M	$128.81M	$64.72M
Working Capital	$281.89M	$360.00M	$242.32M	$155.78M

ENTA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$84.78M	-$103.15M	-$78.76M	-$19.27M
Capital Expenditure	-$2.13M	-$9.06M	-$17.95M	-$12.90M
Free Cash Flow	-$86.91M	-$112.21M	-$96.71M	-$32.17M
Depreciation & Amortisation	$2.97M	$2.37M	$2.34M	$4.59M
Stock-Based Compensation	$26.97M	$28.22M	$26.80M	$18.57M
Investing Cash Flow	$54.90M	-$53.58M	$58.23M	$40.35M
Financing Cash Flow	$20.03M	$198.13M	-$27.63M	-$26.62M
Net Change in Cash	-$9.85M	$41.39M	-$48.16M	-$5.54M

ENTA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$14.93M	$18.31M	$15.13M	$18.61M	$17.16M
Research & Development	$28.07M	$27.21M	$23.81M	$20.86M	$19.44M
Selling, General & Admin	$11.39M	$10.00M	$9.70M	$9.01M	$9.57M
Operating Expenses	$39.45M	$37.21M	$33.51M	$29.87M	$29.01M
Operating Income	-$24.53M	-$18.89M	-$18.39M	-$11.25M	-$11.85M
EBITDA	-$21.03M	-$15.40M	-$15.00M	-$7.60M	-$8.56M
Pretax Income	-$23.95M	-$18.23M	-$18.67M	-$11.91M	-$13.08M
Income Tax	-$1.30M	$29.00K	$32.00K	$24.00K	$7.00K
Net Income	-$22.64M	-$18.25M	-$18.70M	-$11.94M	-$13.09M
Diluted EPS	-1.06	-0.85	-0.87	-0.42	-0.45
Diluted Shares	21.36M	21.38M	21.38M	28.75M	29.04M

ENTA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$60.21M	$44.81M	$32.30M	$37.44M	$34.93M
Receivables	$40.63M	$8.36M	$6.88M	$8.49M	$7.83M
Current Assets	$242.86M	$222.71M	$204.34M	$198.68M	$178.41M
Total Assets	$322.99M	$301.03M	$280.73M	$329.50M	$314.70M
Current Liabilities	$45.95M	$44.55M	$48.55M	$44.73M	$46.44M
Total Debt	$58.73M	$58.05M	$57.90M	$57.07M	$56.54M
Total Liabilities	$229.46M	$221.75M	$216.01M	$202.91M	$198.12M
Retained Earnings	-$367.97M	-$386.23M	-$404.93M	-$416.87M	-$429.96M
Shareholders' Equity	$93.54M	$79.28M	$64.72M	$126.59M	$116.59M
Working Capital	$196.91M	$178.16M	$155.78M	$153.96M	$131.97M

ENTA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$13.49M	$17.51M	-$6.49M	-$11.70M	-$7.16M
Capital Expenditure	-$2.54M	-$155.00K	-$1.46M	-$143.00K	-$15.00K
Free Cash Flow	-$16.03M	$17.35M	-$7.95M	-$11.84M	-$7.17M
Depreciation & Amortisation	$1.20M	$1.21M	$1.28M	$1.23M	$1.21M
Stock-Based Compensation	$4.69M	$4.18M	$4.03M	$3.81M	$3.75M
Investing Cash Flow	-$4.37M	-$26.48M	$2.30M	-$47.30M	$11.94M
Financing Cash Flow	-$6.89M	-$6.42M	-$8.32M	$64.14M	-$7.29M
Net Change in Cash	-$24.74M	-$15.40M	-$12.51M	$5.14M	-$2.51M

Market Snapshot

About

Enanta Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule drugs for viral infections and liver diseases. The company has expertise in protease inhibitors and nucleotide analogs, with development programs targeting respiratory syncytial virus (RSV), hepatitis B virus, and non-alcoholic steatohepatitis (NASH). Enanta has a successful track record, having developed protease inhibitors for hepatitis C that were commercialized through partnerships. The company maintains an internal research and development operation while partnering with larger pharmaceutical companies for commercialization.